- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Facial weakness.
Displaying page 1 of 1.
EudraCT Number: 2020-005215-46 | Sponsor Protocol Number: VS_Nimodipine | Start Date*: 2021-02-19 |
Sponsor Name:Department of Neurosurgery, Medical University of Vienna | ||
Full Title: Intraoperative application of nimodipine to the facial and cochlear nerves during vestibular schwannoma resection to avoid spasm-related postoperative facial paralysis and deafness - a prospective ... | ||
Medical condition: Patients with vestibularis schwanomma undergoing microsurgical resection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005475-41 | Sponsor Protocol Number: MLX | Start Date*: 2014-11-05 |
Sponsor Name:UZ Brussel | ||
Full Title: Sulfamethoxazole treatment of primary PREPL deficiency | ||
Medical condition: Hypotonia-cystinuria syndrome and isolated PREPL deficiency. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003346-27 | Sponsor Protocol Number: ATYR1940-C-003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ATYR PHARMA, INC. | |||||||||||||
Full Title: An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Fa... | |||||||||||||
Medical condition: Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003757-28 | Sponsor Protocol Number: MEX-NM-301 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Lupin Europe GmbH | |||||||||||||
Full Title: An Open-label, non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic Disorders | |||||||||||||
Medical condition: Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2); ICD-10 code G71.1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003096-35 | Sponsor Protocol Number: CORT125134-455 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant | |||||||||||||
Medical condition: Endogenous Cushing syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BG (Completed) AT (Completed) PL (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000899-23 | Sponsor Protocol Number: CORT125134-451 | Start Date*: 2016-08-16 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome | |||||||||||||
Medical condition: Endogenous Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004679-36 | Sponsor Protocol Number: 05 2015-001 | Start Date*: 2006-12-13 | |||||||||||
Sponsor Name:Laboratoire HRA Pharma | |||||||||||||
Full Title: Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. | |||||||||||||
Medical condition: Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
